Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Muscular Dystrophy, Type 2E (LGMD2E) (Beta-Sarcoglycan Deficiency)
Terminated · Phase 1, Phase 2 · NCT03652259
Conditions: Limb-Girdle Muscular Dystrophy, Type 2E
At a glance
- Research payments reported, 2025
- $4,200
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 6
About the trial
- Sponsor
- Sarepta Therapeutics, Inc.
- Tested
- SRP-9003 (genetic)
- Dates
- Started 2018-10-27; completion 2025-01-14
- Results posted
- Not yet
The proposed clinical trial is the first-in-human, single-center, open-label, gene delivery study of SRP-9003 (bidridistrogene xeboparvovec) in participants with LGMD2E.
From ClinicalTrials.gov, last updated 2026-01-20. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sarepta Therapeutics, Inc. reported $4,200 in research payments for this study in 2025 (3 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $4,200
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.